CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies

• With its highly scalable Adenovirus and AAV production technologies, CEVEC provides cutting-edge manufacturing solutions for two of the most widely used gene therapy vectors
• Funding will expand cell line development capacities for ELEVECTA® stable AAV
  producer cell lines
• With ELEVECTA® currently being implemented in a second host cell type, an even stronger demand is expected

Cologne, Germany, July 27, 2021